Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 1

Interventions

Carboplatin 205pembrolizumab 169Pemetrexed 144Cisplatin 126Paclitaxel 78durvalumab 75osimertinib 70Nivolumab 68Docetaxel 66Specimen Handling 64atezolizumab 60Magnetic Resonance Spectroscopy 54Etoposide 47Gemcitabine 46Radiotherapy 45Radiosurgery 40130-nm albumin-bound paclitaxel 36Drug Therapy 33Bevacizumab 29Cetuximab 28Ipilimumab 27cemiplimab 25Taxes 24tislelizumab 21Immunoglobulin G 21Radiation 20Platinum 20Biopsy 20amivantamab 19Disulfides 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
aumolertinib × Thoracic × 90 days × Clear all
NCT04841811 2026-05-22

APPROACH

Guangdong Association of Clinical Trials

Phase 3 Active not recruiting
192 enrolled
Thoracic

Lung Neoplasms

NCT06300424 2026-04-29

NEOVADE

Guangdong Provincial People's Hospital

Phase 2 Active not recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06613633 2026-04-29

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Fudan University

Completed
4,000 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07183189 2026-04-14

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
576 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡